Shots:

• The new PRO results from the P-III trial evaluating Kisqali + ET as adjuvant treatment vs endocrine therapy (ET) alone in 5101 adult patients across 20 countries. The trial is being conducted in collaboration with TRIO
• The results showed that patients maintained physical & social functioning for ~3yrs.; psychological well-being; and overall health scores over baseline & also maintained overall HRQoL when treated with Kisqali, 25.2% reduction in risk of cancer recurrence along with consistent clinical iDFS benefit across key pre-specified subgroups
• All secondary efficacy EPs were also consistent, incl. DDFS & RFS (26% & 28% risk reduction) with a trend for improvement in OS. The safety profile of Kisqali at 400mg was favorable with low rates of symptomatic AEs

Ref: Novartis | Image: Novartis

Related News:- Novartis Reports P-III Trial (NATALEE) Results of Kisqali (ribociclib) for the Treatment of Early Breast Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com